Ewing-Crystal, Nathan A. https://orcid.org/0000-0002-2486-1783
Mroz, Nicholas M. https://orcid.org/0000-0002-4781-8518
Larpthaveesarp, Amara
Lizama, Carlos O. https://orcid.org/0000-0002-0471-8525
Pennington, Remy
Chiaranunt, Pailin https://orcid.org/0000-0001-8753-1469
Dennis, Jason I.
Chang, Anthony A.
Merrill, Eric Dean
Caryotakis, Sofia E.
Kirthivasan, Nikhita https://orcid.org/0009-0005-4864-7799
Teo, Leon
Tsukui, Tatsuya https://orcid.org/0000-0003-3100-6934
Katewa, Aditya
McKinsey, Gabriel L.
Nelson, Sophia C. K. https://orcid.org/0009-0001-9017-8448
Ciesielska, Agnieszka
Lummis, Nicole C.
Pintarić, Lucija https://orcid.org/0000-0003-4577-7334
Dahlgren, Madelene W.
Atakilit, Amha
Paidassi, Helena https://orcid.org/0000-0001-9915-4365
Jain, Saket
Liu, Xiaodan
Xu, Duan
Aghi, Manish K. https://orcid.org/0000-0002-2949-2227
Bourne, James A.
Paz, Jeanne T. https://orcid.org/0000-0001-6339-8130
Daneman, Richard
Gonzalez, Fernando F.
Sheppard, Dean https://orcid.org/0000-0002-6277-2036
Molofsky, Anna V. https://orcid.org/0000-0002-4709-2411
Arnold, Thomas D. https://orcid.org/0000-0002-7310-5597
Molofsky, Ari B. https://orcid.org/0000-0003-0764-3175
Article History
Received: 7 March 2024
Accepted: 23 July 2025
First Online: 3 September 2025
Competing interests
: D.S. and UCSF hold patents on the uses of antibodies that block integrin αvβ8. D.S. is a founder of Pliant Therapeutics and has received research funding from Abbvie, Pfizer, and Pliant Therapeutics. D.S. serves on the Scientific Review Board for Genentech, and on the Inflammation Scientific Advisory Board for Amgen. The remaining authors declare no competing interests.